UniQure advanced its regulatory recovery path for Huntington’s disease, planning a UK marketing application for AMT-130 after a positive meeting with UK regulators. The decision is backed by three-year analyses from ongoing US and Europe trials showing an apparent slowing of disease progression at the highest dose tested. Separately, the company said it expects FDA engagement on potential Phase 3 trial design elements. In vector science, researchers reported AAV2 capsid behavior in the CNS, detailing clearance and neuronal trafficking dynamics—topics that can directly influence translational consistency for AAV-delivered gene therapies. The combination of regulatory planning and vector-mechanics research highlights how gene therapy progress is increasingly constrained by both trial design acceptance and delivery biology—clear bottlenecks that can make or break approvals.